GDFATHER-NEO: what clinicians are saying
visugromab plus nivolumab in muscle-invasive bladder cancer · NCT06059547 ↗ · Phase 2 · CatalYm GmbH
One physician reads GDFATHER-NEO as warranting further investigation, not routine cystectomy avoidance, because pathological response need not translate into survival benefit. A speaker emphasizes response gains and describes tolerability favorably. Another physician questions the low nivolumab activity while cautioning against cross-trial comparisons. Recurrence-free observations concern only pathological complete responders, leaving durable bladder preservation uncertain.
Created with AI · how we check it
- edition 2
- commentary checked Nov 18, 2026
- 112 verified statements
This edition $750, with MCP access for your AI agent. Get this report
8 findings, and what sits behind each
01. Cystectomy omission: why a clinician sees proof of concept as insufficient
1 of the report's 10 cited clinicians · 7 statements from 3 speakers in 4 sources, 1 of them a podcast or video · 4 passages
Limitations recorded: 2.
Draws on: Secondary endpoints, Primary endpoint: Pathological complete response rate, Primary endpoint: Radiological response rate according RECIST, The comparison, Safety and tolerability, Design and conduct.
02. Response gap: most speakers limit inference; a clinician questions control responses
2 of the report's 10 cited clinicians · 10 statements from 5 speakers in 8 sources, 5 of them podcasts or videos · 8 passages
Limitations recorded: 2.
Draws on: The comparison, Design and conduct, Primary endpoint: Pathological complete response rate, Primary endpoint: Radiological response rate according RECIST, Population and setting, Safety and tolerability.
03. GDFATHER-NEO: what most speakers highlight in the size of the response difference
6 of the report's 10 cited clinicians · 14 statements from 8 speakers in 11 sources, 2 of them podcasts or videos · 11 passages
Limitations recorded: 3.
Draws on: The comparison, Primary endpoint: Pathological complete response rate, Primary endpoint: Radiological response rate according RECIST, Safety and tolerability, Secondary endpoints, Design and conduct.
04. Curative care: speakers note tolerability; one seeks no added toxicity
1 of the report's 10 cited clinicians · 7 statements from 4 speakers in 6 sources, 2 of them podcasts or videos · 7 passages
Limitations recorded: 3.
Draws on: Safety and tolerability, Primary endpoint: Pathological complete response rate, Secondary endpoints, Primary endpoint: Radiological response rate according RECIST, The comparison, Design and conduct.
05. GDF-15 blockade: why a clinician would test biology-guided, less invasive treatment
1 of the report's 10 cited clinicians · 9 statements from 4 speakers in 5 sources, 3 of them podcasts or videos · 6 passages
Limitations recorded: 2.
Draws on: Population and setting, Secondary endpoints.
06. MIBC care: a speaker sees possible shifts; a clinician expects better results
1 of the report's 10 cited clinicians · 6 statements from 3 speakers in 4 sources · 4 passages
Limitations recorded: 4.
Draws on: Population and setting, The comparison, Design and conduct.
Beyond the trial population
07. GDF-15 combinations: how a speaker envisions de-escalation in deep responders
No named clinician · accounts and unnamed speakers · 7 statements from 2 speakers in 7 sources, 2 of them podcasts or videos · 7 passages
Limitations recorded: 3.
08. European clinical research: why a speaker calls for urgent changes
No named clinician · accounts and unnamed speakers · 2 statements from 1 speaker in 2 sources · 2 passages
Limitations recorded: 1.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 8
1 of the report's 10 cited clinicians
Cystectomy omission: why a clinician sees proof of concept as insufficient
7 statements from 3 speakers in 4 sources, 1 of them a podcast or video
1 of the 3 named speakers in this finding holds this view, a confirmed clinician
- 7
- statements
- 4
- passages
- 4
- sources
- 3
- speakers
What the statements areViews 4Questions and uncertainty 1Clinical experience 0Comparisons 0Restated results and context 2Statement-to-passage links (a passage can back several statements)Supporting a statement 7Giving context 1Recorded with the findingLimitations: 2
3 posts and articles · 1 podcast or video
Draws on: Secondary endpoints, Primary endpoint: Pathological complete response rate, Primary endpoint: Radiological response rate according RECIST, The comparison, Safety and tolerability, Design and conduct.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
2 of the 8 findings and 9 of the 112 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (4)
HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; RECIST, Response Evaluation Criteria in Solid Tumors.
The full GDFATHER-NEO report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say larger prospective trials with longer follow-up must establish about event-free survival and bladder preservation before considering cystectomy omission after neoadjuvant visugromab plus nivolumab in muscle-invasive bladder cancer?
From finding F1 (7 statements from 3 speakers in 4 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 70commentary sources screened
- 40sources cited by verified statements
- 15named in screened sources
- 15speakers cited in the report
- 14cited speakers with a verified identity
10 cited clinicians, speakers with a confirmed clinical role, of them 10 physicians. By role and specialty:
- 6 physician, Medical oncology
- 4 physician, specialty not confirmed
Also in the sources: 5 organizational or shared accounts, not counted as people.
- 112verified statements, each linked to its source
- 29of them from speakers with a confirmed clinical role
- 8findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 112 | Paid |
| Who said each statement: the cited speakers | 15 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 10 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 14 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 13 | Free |
| Sources with links | 40 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
13 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Pathological complete response rate | 28 | 26 |
| Primary endpoint: Radiological response rate according RECIST | 20 | 19 |
| Secondary endpoints | 23 | 14 |
| Population and setting | 16 | 11 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 35 | 24 |
| Safety and tolerability | 24 | 20 |
| Design and conduct | 17 | 15 |
| Response-conditioned bladder preservation and limits on changing surgery | 19 | 12 |
| Immune-resistance rationale and investigational biological selection | 20 | 10 |
| Neoadjuvant MIBC positioning amid evolving perioperative alternatives | 8 | 5 |
| Untested combinations and proposed de-escalation in deep responders | 7 | 7 |
| European clinical-research environment | 2 | 2 |
| Study novelty, evaluative reactions and wider GDF-15 visibility | 11 | 7 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
112 verified statements from 40 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 44 statements · 39% | ||||
| YouTube | 39 | 5 | 5 | |
| Podcasts | 5 | 1 | 1 | |
| Posts · 65 statements · 58% | ||||
| X threads | 40 | 24 | 52 | |
| LinkedIn posts | 21 | 6 | 7 | |
| Bluesky threads | 4 | 3 | 5 | |
| Primary sources · 3 statements · 3%cited for context, not screened | ||||
| Publications | 3 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 29 / quarter
- Screened window
- Jan 27, 2024 → Nov 9, 2026
- Cited window
- Sep 23, 2025 → Nov 9, 2026
- Retrieved
- Nov 17, 2026
The trial
from ClinicalTrials.gov- Title
- A Multi-center Phase 2 Study of Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for the Treatment of Muscle Invasive Bladder Cancer
- Registry
- NCT06059547
- Study IDs
- CTL-002-002
- Sponsor
- CatalYm GmbH
- Design
- Phase 2 · Interventional, non randomized, parallel
- Status
- Completed
- Enrollment
- 31 actual
- Registered
- 2023-09-28
- Start
- 2023-09-06 actual
- Primary completion
- 2025-10-16 actual
- Primary endpoints
- Pathological complete response rate
- Radiological response rate according RECIST
- Interventions
- 3 registered
More on: Urothelial carcinoma, nivolumab, visugromab
Discussed at: ESMO Congress 2026
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on integrating circulating and urinary tumour DNA to predict response and recurrence after neoadjuvant bladder cancer therapy; a view on ctDNA and utDNA for predicting pathological response and recurrence-free survival after neoadjuvant treatment in muscle-invasive bladder cancer.
- 45 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 6 sources about other trials or topics are not included.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Organizational accounts, congratulatory reactions, relays and repeated versions of discussions should not be counted as independent clinician endorsements.
Show all 11 known gaps +Fewer −
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The publication describes nonrandomized allocation, whereas some interview accounts say randomized. Response labels, major-response rates and control percentages also vary between accounts; these differences prevent a single harmonized rendering of what everyone reported.
- Favorable recurrence follow-up is restricted to response-defined subgroups and remains short. It does not establish a whole-population survival advantage or the long-term safety of bladder preservation.
- Coverage concentrated on trial names and identifiers. Relevant discussion using unnamed references, variant spellings or different transcription may be absent.
- No trial protocol or exact regulatory label for visugromab was available among the sources reviewed. This limits detailed assessment of methods and regulatory positioning; it does not establish the drug's regulatory status.
- Expectations about later presentations or readouts are preserved at the timing stated in the sources and are not evidence of what those later studies showed.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 18, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. GDFATHER-NEO (NCT06059547): HCP commentary report. Edition 2, v1.1.0. Accepted Nov 18, 2026. https://www.erudio.com/reports/gdfather-neo-nct06059547
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "GDFATHER-NEO" (NCT06059547), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "gdfather-neo-nct06059547". If you cannot make requests, read https://www.erudio.com/reports/gdfather-neo-nct06059547.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06059547", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06059547 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/gdfather-neo-nct06059547.json
curl https://www.erudio.com/reports/gdfather-neo-nct06059547.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "gdfather-neo-nct06059547" })release c177f4922bb1964feb5b89d1939380fc79c95ec36f5bd62b19794815b9d06a15
Questions
How much does the GDFATHER-NEO report cost?
One edition costs $750 (Focused · 112 verified statements · 29 from 10 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the GDFATHER-NEO report cover?
112 statements from 40 sources (1 podcast, 5 videos, 33 posts, 1 paper), 29 of them from 10 confirmed clinicians, each linked to its source. Commentary checked Nov 18, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the GDFATHER-NEO report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "gdfather-neo-nct06059547" }) previews it and create_order({ "report": "gdfather-neo-nct06059547", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the GDFATHER-NEO report?
Edition 2 (version 1.1.0), accepted Nov 18, 2026 UTC; last checked for new commentary Nov 18, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.